Company News

Lysoway Therapeutics has received a research grant from the Silverstein Foundation to investigate the therapeutic potential of its lysosomal ion channel modulators in GBA-deficient Parkinson’s disease

Cambridge, MA and New York, NY, Jan. 5, 2023 – Lysoway Therapeutics, a startup biotech developing small molecule modulators of lysosomal ion channels and leader in lysosomal ion channel disease biology, announced today receiving a research grant from the Silverstein Foundation for Parkinson’s with GBA.

“We appreciate the generous support from the Silverstein Foundation, which underlines the importance of lysosomal ion channels as drug targets for Parkinson’s disease.” said Dr. Yongchang Qiu, chief executive officer of Lysoway Therapeutics. “This grant and our relationship with the Silverstein Foundation will bring us closer to the Parkinson’s disease research community and expedite our overall translational research effort. Lysoway plans to use the grant to investigate the therapeutic potential of its channel modulators in preclinical models of GBA-deficient Parkinson’s disease, particularly focusing on discovery and development of target engagement and pharmacodynamic biomarkers.”

About Lysoway Therapeutics

Lysoway Therapeutics is a leader in lysosomal ion channel disease biology. We have developed unique technological approaches to screen and develop potent modulators of lysosomal ion channels, including TRPML1 and TMEM175. These ion channels are essential transducers of cellular signals and are required to help maintain cellular homeostasis, especially the delicate balance within the autophagy/lysosomal pathway, which is often disrupted in a number of pathological conditions. Lysoway’s small molecule modulators have great potential to re-balance lysosomal function and autophagy to treat neurodegenerative diseases with lysosomal deficiency and rare diseases characterized by toxic accumulation of cellular wastes.

About The Silverstein Foundation for Parkinson’s with GBA

The Silverstein Foundation is a 501(c)(3) non-profit organization focused on investing in cutting-edge therapeutic approaches for the treatment and prevention of Parkinson’s disease in glucocerebrosidase (GBA-PD) mutation carriers. The Foundation collaborates with clinicians, scientists, and biotechnology companies to accelerate research and clinical trials in an effort to rapidly bring new disease-modifying therapeutic options to patients. The Foundation has funded 39 projects across a diverse set of therapeutic approaches since its inception in 2017. The Foundation applies a unique flexible funding model including both new company formation and traditional research grants to deliver in real-time on its mission of rapidly developing novel treatments for GBA-PD patients.

Contact Info